BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bozward AG, Warricker F, Oo YH, Khakoo SI. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. Front Immunol 2021;12:643310. [PMID: 33995362 DOI: 10.3389/fimmu.2021.643310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Chiang Y, Hsu F, Tsai C, Cheng JC. Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma. Front Oncol 2022;12:1009089. [DOI: 10.3389/fonc.2022.1009089] [Reference Citation Analysis]
2 Peng H, Zhu E, Zhang Y. Advances of cancer-associated fibroblasts in liver cancer. Biomark Res 2022;10:59. [PMID: 35971182 DOI: 10.1186/s40364-022-00406-z] [Reference Citation Analysis]
3 Guo C, Tang Y, Yang Z, Li G, Zhang Y. Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates. Front Immunol 2022;13:958161. [DOI: 10.3389/fimmu.2022.958161] [Reference Citation Analysis]
4 Dios-barbeito S, González R, Cadenas M, García LF, Victor VM, Padillo FJ, Muntané J. Impact of nitric oxide in liver cancer microenvironment. Nitric Oxide 2022. [DOI: 10.1016/j.niox.2022.07.006] [Reference Citation Analysis]
5 Sajid M, Liu L, Sun C. The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications. Front Immunol 2022;13:887186. [PMID: 35669776 DOI: 10.3389/fimmu.2022.887186] [Reference Citation Analysis]
6 Jin X, Zhang S, Wang N, Guan L, Shao C, Lin Y, Liu J, Li Y. High Expression of TGF-β1 Contributes to Hepatocellular Carcinoma Prognosis via Regulating Tumor Immunity. Front Oncol 2022;12:861601. [PMID: 35547872 DOI: 10.3389/fonc.2022.861601] [Reference Citation Analysis]
7 Cucarull B, Tutusaus A, Rider P, Hernáez-Alsina T, Cuño C, García de Frutos P, Colell A, Marí M, Morales A. Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers (Basel) 2022;14:621. [PMID: 35158892 DOI: 10.3390/cancers14030621] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
8 Goggi JL, Ramasamy B, Tan YX, Hartimath SV, Tang JR, Cheng P, Msallam R, Chacko A, Hwang YY, Robins EG, Bogdanov A. Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma. Molecular Imaging 2021;2021:1-8. [DOI: 10.1155/2021/9305277] [Reference Citation Analysis]
9 Ronca V, Bozward AG, Oo YH. Use of immunosuppression in non-transplant hepatology. Best Pract Res Clin Gastroenterol 2021;54-55:101760. [PMID: 34874849 DOI: 10.1016/j.bpg.2021.101760] [Reference Citation Analysis]
10 Zheng X, Jin W, Wang S, Ding H. Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:729705. [PMID: 34566989 DOI: 10.3389/fimmu.2021.729705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
11 Jacquelot N, Seillet C, Souza-Fonseca-Guimaraes F, Sacher AG, Belz GT, Ohashi PS. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Int J Mol Sci 2021;22:9044. [PMID: 34445750 DOI: 10.3390/ijms22169044] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Blidisel A, Marcovici I, Coricovac D, Hut F, Dehelean CA, Cretu OM. Experimental Models of Hepatocellular Carcinoma-A Preclinical Perspective. Cancers (Basel) 2021;13:3651. [PMID: 34359553 DOI: 10.3390/cancers13153651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]